Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 8Terminated 3Withdrawn 2Unknown 1

Sponsor Class

OTHER 20NIH 5NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Recurrence 1

Interventions

Radiotherapy 41Cisplatin 36Fluorouracil 17Paclitaxel 15Docetaxel 14Cyclophosphamide 14Carboplatin 14Filgrastim 13Doxorubicin 13Gemcitabine 11Etoposide 11Capecitabine 10Surgical Procedures, Operative 9Methotrexate 9Leucovorin 9Chemotherapy, Adjuvant 9Vincristine 8Peripheral Blood Stem Cell Transplantation 8Oxaliplatin 8Dexamethasone 7Bevacizumab 7Topotecan 6Radiotherapy, Conformal 6Prednisone 6Fenretinide 6Cetuximab 6Neoadjuvant Therapy 5Mitomycin 5Irinotecan 5Ifosfamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × NETWORK × Thalidomide × Clear all
NCT00256776 2021-10-18

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

European Society for Blood and Marrow Transplantation

Phase 3 Terminated
269 enrolled 9 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT00124579 2018-08-09

S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Terminated
7 enrolled 6 charts
Plasma cell

Multiple Myeloma

NCT00005834 2015-03-06

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

SWOG Cancer Research Network

Phase 3 Terminated
19 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡